{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:38:04Z","timestamp":1784763484233,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"national natural science foundation of china, regional project","award":["No. 81960032"],"award-info":[{"award-number":["No. 81960032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to evaluate the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion (DLI) in treating patients with relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Twenty-six AML patients who relapsed after allo-HSCT were enrolled and treated with venetoclax plus azacitidine and DLI. Complete remission with incomplete recovery (CRi), partial remission (PR), and objective remission rate (ORR) were assessed, and then event-free survival (EFS) and overall survival (OS) were evaluated. Besides, adverse events were documented. Additionally, whole exome sequencing was performed in bone marrow samples. The CRi, PR, and ORR rates were 26.9%, 34.6%, and 61.5%, respectively. The median time of EFS and OS was 120 (95% CI: 71\u2013610) days and 284.5 (95% CI: 81\u2013610) days, respectively. The most common adverse events were hematologic system adverse events including agranulocytosis, anemia, and thrombocytopenia, while the adverse events of other systems were relatively less and milder. In addition, no serious adverse events existed. Of note, there were 6 (23.1%) patients who developed GVHD. As for gene mutation, 49 mutated genes were found, which were categorized as first-, second-, and third-class mutations, and then further analysis revealed that the first-class mutations were not correlated with EFS or OS. Additionally, the most frequent mutated genes were FLT3, CEBPA, DNMT3A, KIT, KRAS, and NRAS. Venetoclax plus azacitidine and DLI is efficient and tolerant in treating patients with relapsed AML after allo-HSCT, implying this combined therapy as a potential treatment option in the studied patients.<\/jats:p>","DOI":"10.1007\/s00277-021-04674-x","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T02:02:53Z","timestamp":1632708173000},"page":"119-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"101","author":[{"given":"Peng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shisi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-2283","authenticated-orcid":false,"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"issue":"14","key":"4674_CR1","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2217\/fon-2019-0670","volume":"16","author":"K Saleh","year":"2020","unstructured":"Saleh K, Khalifeh-Saleh N, Kourie HR (2020) Acute myeloid leukemia transformed to a targetable disease. Future Oncol 16(14):961\u2013972. https:\/\/doi.org\/10.2217\/fon-2019-0670","journal-title":"Future Oncol"},{"issue":"3","key":"4674_CR2","first-page":"38","volume":"103","author":"A Pelcovits","year":"2013","unstructured":"Pelcovits A (2013) Niroula R (2020) Acute myeloid leukemia: a review. R I Med J 103(3):38\u201340","journal-title":"R I Med J"},{"key":"4674_CR3","doi-asserted-by":"publisher","unstructured":"Ferrara F, Lessi F, Vitagliano O, Birkenghi E, Rossi G (2019) Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia. Cancers (Basel) 11 (2). https:\/\/doi.org\/10.3390\/cancers11020224","DOI":"10.3390\/cancers11020224"},{"issue":"8","key":"4674_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40266-015-0285-6","volume":"32","author":"JC Bryan","year":"2015","unstructured":"Bryan JC, Jabbour EJ (2015) Management of relapsed\/refractory acute myeloid leukemia in the elderly: current strategies and developments. Drugs Aging 32(8):623\u2013637. https:\/\/doi.org\/10.1007\/s40266-015-0285-6","journal-title":"Drugs Aging"},{"issue":"2","key":"4674_CR5","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.3324\/haematol.2018.199794","volume":"104","author":"ML Hutter-Kronke","year":"2019","unstructured":"Hutter-Kronke ML, Fiedler W, Kundgen A, Krauter J, von Lilienfeld-Toal M, Dohner H, Schlenk RF (2019) Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. Haematologica 104(2):e63\u2013e64. https:\/\/doi.org\/10.3324\/haematol.2018.199794","journal-title":"Haematologica"},{"issue":"2","key":"4674_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/MOH.0b013e3283257a87","volume":"16","author":"LM Arfons","year":"2009","unstructured":"Arfons LM, Tomblyn M, Rocha V, Lazarus HM (2009) Second hematopoietic stem cell transplantation in myeloid malignancies. Curr Opin Hematol 16(2):112\u2013123. https:\/\/doi.org\/10.1097\/MOH.0b013e3283257a87","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"4674_CR7","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1007\/s00726-015-2019-9","volume":"47","author":"T Nemkov","year":"2015","unstructured":"Nemkov T, D\u2019Alessandro A, Hansen KC (2015) Three-minute method for amino acid analysis by UHPLC and high-resolution quadrupole orbitrap mass spectrometry. Amino Acids 47(11):2345\u20132357. https:\/\/doi.org\/10.1007\/s00726-015-2019-9","journal-title":"Amino Acids"},{"issue":"2","key":"4674_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, Majeti R (2015) Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 21(2):178\u2013184. https:\/\/doi.org\/10.1038\/nm.3788","journal-title":"Nat Med"},{"issue":"9","key":"4674_CR9","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1111\/cas.15048","volume":"112","author":"Y Wei","year":"2021","unstructured":"Wei Y, Xiong X, Li X, Lu W, He X, Jin X, Sun R, Lyu H, Yuan T, Sun T, Zhao M (2021) Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci 112(9):3636\u20133644. https:\/\/doi.org\/10.1111\/cas.15048","journal-title":"Cancer Sci"},{"issue":"2","key":"4674_CR10","doi-asserted-by":"publisher","first-page":"E48","DOI":"10.1002\/ajh.25352","volume":"94","author":"G Andreani","year":"2019","unstructured":"Andreani G, Dragani M, Serra A, Nicoli P, De Gobbi M, Cilloni D (2019) Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation. Am J Hematol 94(2):E48\u2013E50. https:\/\/doi.org\/10.1002\/ajh.25352","journal-title":"Am J Hematol"},{"issue":"8","key":"4674_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40265-016-0585-0","volume":"76","author":"LJ Scott","year":"2016","unstructured":"Scott LJ (2016) Azacitidine: a review in myelodysplastic syndromes and acute myeloid leukaemia. Drugs 76(8):889\u2013900. https:\/\/doi.org\/10.1007\/s40265-016-0585-0","journal-title":"Drugs"},{"issue":"1","key":"4674_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"issue":"7","key":"4674_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Illes A, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"24","key":"4674_CR14","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, International Working Group for Diagnosis SoRCTO, Reporting Standards for Therapeutic Trials in Acute Myeloid L","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, International Working Group for Diagnosis SoRCTO, Reporting Standards for Therapeutic Trials in Acute Myeloid L (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642\u20134649. https:\/\/doi.org\/10.1200\/JCO.2003.04.036","journal-title":"J Clin Oncol"},{"issue":"22","key":"4674_CR15","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, Kalicki-Veizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059\u20132074. https:\/\/doi.org\/10.1056\/NEJMoa1301689","journal-title":"N Engl J Med"},{"issue":"23","key":"4674_CR16","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O\u2019Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Dohner K, Schlenk RF, Dohner H, Campbell PJ (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209\u20132221. https:\/\/doi.org\/10.1056\/NEJMoa1516192","journal-title":"N Engl J Med"},{"key":"4674_CR17","unstructured":"\u6c5d\u6606 (2019) \u300a\u4e8c\u4ee3\u6d4b\u5e8f\u6280\u672f\u5728\u8840\u6db2\u80bf\u7624\u4e2d\u7684\u5e94\u7528\u4e2d\u56fd\u4e13\u5bb6\u5171\u8bc6(2018\u5e74\u7248)\u300b\u89e3\u8bfb. \u4e34\u5e8a\u8840\u6db2\u5b66\u6742\u5fd7 32 (03):20\u201322+26"},{"issue":"3","key":"4674_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93(3):401\u2013407. https:\/\/doi.org\/10.1002\/ajh.25000","journal-title":"Am J Hematol"},{"issue":"9","key":"4674_CR19","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1080\/10428194.2020.1761964","volume":"61","author":"C Ganzel","year":"2020","unstructured":"Ganzel C, Ram R, Gural A, Wolach O, Gino-Moor S, Vainstein V, Nachmias B, Apel A, Koren-Michowitz M, Pasvolsky O, Yerushalmi R, Danylesko I, Cohen Y, Peretz G, Moshe Y, Zektser M, Yeganeh S, Rowe JM, Ofran Y (2020) Venetoclax is safe and efficacious in relapsed\/refractory AML. Leuk Lymphoma 61(9):2221\u20132225. https:\/\/doi.org\/10.1080\/10428194.2020.1761964","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"4674_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H (2019) Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov 9(3):370\u2013383. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0774","journal-title":"Cancer Discov"},{"issue":"5","key":"4674_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/bmt.2015.10","volume":"50","author":"J Steinmann","year":"2015","unstructured":"Steinmann J, Bertz H, Wasch R, Marks R, Zeiser R, Bogatyreva L, Finke J, Lubbert M (2015) 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft. Bone Marrow Transplant 50(5):690\u2013695. https:\/\/doi.org\/10.1038\/bmt.2015.10","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4674_CR22","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00277-021-04398-y","volume":"100","author":"O Amit","year":"2021","unstructured":"Amit O, On YB, Perez G, Shargian-Alon L, Yeshurun M, Ram R (2021) Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial Ann Hematol 100(3):817\u2013824. https:\/\/doi.org\/10.1007\/s00277-021-04398-y","journal-title":"A retrospective multicenter trial Ann Hematol"},{"key":"4674_CR23","doi-asserted-by":"publisher","unstructured":"Medeiros BC, Tanaka TN, Balaian L, Bashey A, Guzdar A, Li H, Messer K, Ball ED (2018) A phase I\/II trial of the combination of azacitidine and gemtuzumab ozogamicin for treatment of relapsed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 18 (5):346\u2013352 e345. https:\/\/doi.org\/10.1016\/j.clml.2018.02.017","DOI":"10.1016\/j.clml.2018.02.017"},{"key":"4674_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2016.07.010","volume":"49","author":"A Ghobadi","year":"2016","unstructured":"Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, Westervelt P (2016) Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leuk Res 49:1\u20136. https:\/\/doi.org\/10.1016\/j.leukres.2016.07.010","journal-title":"Leuk Res"},{"key":"4674_CR25","doi-asserted-by":"publisher","unstructured":"Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS (2021) NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw 19 (1):16\u201327. https:\/\/doi.org\/10.6004\/jnccn.2021.0002","DOI":"10.6004\/jnccn.2021.0002"},{"key":"4674_CR26","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2021_201230N1426","author":"M Wu","year":"2021","unstructured":"Wu M, Guo ZW, Huang GN, Ye YB (2021) Features and impacts on the prognosis of gene mutations in patients with acute myeloid leukemia. Neoplasma. https:\/\/doi.org\/10.4149\/neo_2021_201230N1426","journal-title":"Neoplasma"},{"key":"4674_CR27","doi-asserted-by":"publisher","first-page":"153303382110049","DOI":"10.1177\/15330338211004933","volume":"20","author":"Y Lai","year":"2021","unstructured":"Lai Y, Sheng L, Wang J, Zhou M, OuYang G (2021) A novel 85-gene expression signature predicts unfavorable prognosis in acute myeloid leukemia. Technol Cancer Res Treat 20:15330338211004932. https:\/\/doi.org\/10.1177\/15330338211004933","journal-title":"Technol Cancer Res Treat"},{"key":"4674_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.628248","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Cai W, Cai P, Zhang L, Yao H, Zhang T, Shen H, Chen S (2021) Prognostic nomogram for acute myeloid leukemia patients with biallelic CEBPA mutations. Front Oncol 11:628248. https:\/\/doi.org\/10.3389\/fonc.2021.628248","journal-title":"Front Oncol"},{"key":"4674_CR29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004136","author":"G Onate","year":"2021","unstructured":"Onate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol MA, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M (2021) Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2020004136","journal-title":"Blood Adv"},{"issue":"9","key":"4674_CR30","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1016\/j.sjbs.2021.07.012","volume":"28","author":"A Rehman","year":"2021","unstructured":"Rehman A, Akram AM, Chaudhary A, Sheikh N, Hussain Z, Alsanie WF, Rehman RA, Hameed N, Saleem T, Zafar A, Absar M, Iqbal Z, Alhazmi A, Baeshen HA, Mohammedsaleh ZM, Qamer S, Sayed S, Gaber A (2021) RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients. Saudi J Biol Sci 28(9):4845\u20134851. https:\/\/doi.org\/10.1016\/j.sjbs.2021.07.012","journal-title":"Saudi J Biol Sci"},{"issue":"9","key":"4674_CR31","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O\u2019Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V (2018) Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica 103(9):e404\u2013e407. https:\/\/doi.org\/10.3324\/haematol.2018.188094","journal-title":"Haematologica"},{"issue":"5","key":"4674_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/sj.bmt.1705898","volume":"41","author":"AW Loren","year":"2008","unstructured":"Loren AW, Porter DL (2008) Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 41(5):483\u2013493. https:\/\/doi.org\/10.1038\/sj.bmt.1705898","journal-title":"Bone Marrow Transplant"},{"key":"4674_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.562558","volume":"10","author":"B Samra","year":"2020","unstructured":"Samra B, Konopleva M, Isidori A, Daver N, DiNardo C (2020) Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions. Front Oncol 10:562558. https:\/\/doi.org\/10.3389\/fonc.2020.562558","journal-title":"Front Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04674-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T15:09:39Z","timestamp":1641222579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04674-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4674"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04674-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of The Affiliated Hospital of Guizhou Medical University and was performed in line with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All participants signed informed consent forms.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}